5GMQ

Structure of MERS-CoV RBD in complex with a fully human antibody MCA1

5GMQ の概要

• エントリーDOI: 10.2210/pdb5gmq/pdb
• 分子名称: S protein, MCA1 heavy chain, MCA1 light chain, ... (6 entities in total)
• 機能のキーワード: viral protein-immune system complex, viral protein/immune system
• 由来する生物種: Middle East respiratory syndrome coronavirus; 詳細
• タンパク質・核酸の鎖数: 3
• 化学式量合計: 73761.35

構造登録者

Chen, C.,Wang, J.M.,Zou, T.T.,Gao, X.P.,Cui, S.,Jin, Q. (登録日: 2016-07-15, 公開日: 2017-05-31, 最終更新日: 2024-11-20)

主引用文献

Chen, Z.,Bao, L.,Chen, C.,Zou, T.,Xue, Y.,Li, F.,Lv, Q.,Gu, S.,Gao, X.,Cui, S.,Wang, J.,Qin, C.,Jin, Q.
Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset.
J. Infect. Dis., 215:1807-1815, 2017

PubMed Abstract: Middle East respiratory syndrome coronavirus (MERS-CoV) infection in humans is highly lethal, with a fatality rate of 35%. New prophylactic and therapeutic strategies to combat human infections are urgently needed. We isolated a fully human neutralizing antibody, MCA1, from a human survivor. The antibody recognizes the receptor-binding domain of MERS-CoV S glycoprotein and interferes with the interaction between viral S and the human cellular receptor human dipeptidyl peptidase 4 (DPP4). To our knowledge, this study is the first to report a human neutralizing monoclonal antibody that completely inhibits MERS-CoV replication in common marmosets. Monotherapy with MCA1 represents a potential alternative treatment for human infections with MERS-CoV worthy of evaluation in clinical settings.

PubMed: 28472421
DOI: 10.1093/infdis/jix209

実験手法

X-RAY DIFFRACTION (2.703 Å)